Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies

The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) erlotinib has been approved for years as a first-line therapy for patients harboring EGFR-sensitizing mutations. With the promising implementation of immunotherapeutic strategies for the treatment of lung cancer, there is a gr...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cell Death Dis
Main Authors: Dominguez, Charli, Tsang, Kwong-Yok, Palena, Claudia
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2016
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5059888/
https://ncbi.nlm.nih.gov/pubmed/27685624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2016.297
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares